Oncology – Wang
Professor Zhi Wang
617-414-1777
zwang@bu.edu
Options: UROP
Skin and oral cancers are common malignancies at field of Otolaryngology Head Neck Surgery, in the United States. Current agents and strategies used in clinic are far from being satisfactory, and new approach is highly desired. Recent studies showed that recently FDA-approved Suberoylanilide hydroxamic acid (SAHA) has great potential as a new agent for cancer chemotherapy, due to its treatment efficacy and particularly safety. Unfortunately, this agent alone did not demonstrate such efficacy for both cancers, regardless of encouraging results from other tumors. In this study, we will determine if SAHA will become effective, if combining it with either of low-dose retinoic acid (RA) or cisplatin, in cultured cell lines and tumor xenografts of nude mouse skin model. This is the first study to use this SAHA co-treatment for treating such cancers, and we expect its success will have great benefits to clinic.